Endocrine Abstracts

Castration-resistant prostate cancer (CRPC) is an androgen-independent subtype of prostate cancer (PCa) that develops in response to androgen deprivation therapy (ADT). In some advanced CRPC cases, tumors can develop the neuroendocrine (NE) phenotype and progress towards an aggressive PCa subtype known as treatment-induced NE PCa (NEPC), which is characterized by an increase in the population of NE cells that secrete neuropeptides promoting cancer progression. A key player in ...